60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial

60 DEGREES PHARMACEUTICALS, INC.

Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.
Phase IIb will combine SJ733 (oral ATP4 inhibitor) with tafenoquine for radical cure of Plasmodium vivax malaria.
Study funded by Global Health Innovative Technology Fund; Eisai managing trial material manufacturing and non-clinical studies.
60 Degrees Pharma will supply tafenoquine and placebos as study drugs for the trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.